Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway

Scinai Immunotherapeutics CEO Amir Reichman reported on October 20, 2026, that the company's contract development and manufacturing organization (CDMO) business has seen significant growth, with committed customer orders rising to approximately $8.1 million from $1.9 million at the end of 2025. This growth is attributed to a new agreement with a U.S.-based biopharmaceutical company, which includes $5.1 million in base service fees and potential for total opportunities exceeding $10 million. Additionally, with about $5.3 million in net proceeds from recent financing, Scinai's operating runway is estimated to extend to late 2027, with possibilities for further extension into Q3 2028.